Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04197310 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib and Nivolumab for Carcinoid Tumors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT04197310 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT04197310, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. \- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-12-26 |
| Est. Completion | 2024-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04197310
The ClinicalTrials.gov registry entry for NCT04197310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04197310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04197310 about?
NCT04197310 is a clinical study titled "Cabozantinib and Nivolumab for Carcinoid Tumors". This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. \- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
What is the current status of trial NCT04197310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-12-26. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04197310?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04197310?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.